Skip to main content
OpenTrials

Clinical trial condition

Urologic Diseases

Explore clinical trials studying Urologic Diseases. Study availability and eligibility vary by location and protocol.

13,717 public trials 2,164 recruiting studies
Refine in advanced search Browse all conditions

Urologic Diseases trial results

Active, not recruiting

Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]

NCT03504163

Conditions
Bladder Cancer, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +9 more
Locations
  • Memorial Sloan Kettering Basking Ridge (All Protocol Activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (All Protocol Activities) Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen (All protocol activities) Montvale, New Jersey, United States
  • Memorial Sloan Kettering Commack (All protocol activities) Commack, New York, United States
View Trial Details
Active, not recruiting

Cancer and Blood Pressure Management, CARISMA Study

NCT04467021

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Medullary, +36 more
Locations
  • Siteman Cancer Center at West County Hospital Creve Coeur, Missouri, United States
  • Washington University School of Medicine St Louis, Missouri, United States
  • Montefiore Medical Center-Einstein Campus The Bronx, New York, United States
  • Montefiore Medical Center-Weiler Hospital The Bronx, New York, United States
View all 25 locations
View Trial Details
Active, not recruiting

Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO

NCT05078047

Conditions
Adenocarcinoma, Basal Cell Carcinoma, Breast Diseases, +69 more
Locations
  • Institut de cancérologie de l'Ouest Angers, France
  • Clinique Sainte Catherine Avignon, France
  • Centre Hospitalier de la Côte Basque Bayonne, France
  • CHU Bordeaux - Hôpial Saint André Bordeaux, France
View all 33 locations
View Trial Details
Active, not recruiting

IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer

NCT05843448

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma, +12 more
Locations
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
View Trial Details
Active, not recruiting

Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.

NCT05501054

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • Duke Cancer Institute Durham, North Carolina, United States
  • Abramson Cancer Center of the University of Pennsylvania Philadelphia, Pennsylvania, United States
  • M D Anderson Cancer Center Houston, Texas, United States
View Trial Details
Active, not recruiting

Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

NCT04700124

Conditions
Bladder Cancer, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +10 more
Locations
  • Mayo Clinic in Arizona - Phoenix ( Site 0043) Phoenix, Arizona, United States
  • St Joseph Heritage Healthcare-Oncology ( Site 0035) Fullerton, California, United States
  • UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro ( Site 0005) Los Angeles, California, United States
  • University of California San Francisco ( Site 0010) San Francisco, California, United States
View all 188 locations
View Trial Details

Related conditions